REG 174 INFORMATION FOR UK HEALTHCARE PROFESSIONALS /Pfizer and BioNTech's Covid-19 vaccine BNT162b2
This medicinal product does not have a UK marketing authorisation but has been given authorisation for temporary supply by the UK Department of Health and Social Care and the Medicines & Healthcare products Regulatory Agency for active immunization to prevent COVID-19 disease caused by SARS-CoV-2 virus in individuals aged 16 years of age and over.
As with any new medicine in the UK, this product will be closely monitored to allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. See section 4.8 for how to report adverse reactions.
- NAME OF THE MEDICINAL PRODUCT
COVID-19 mRNA Vaccine BNT162b2 concentrate for solution for injection
- QUALITATIVE AND QUANTITATIVE COMPOSITION